Evidence map›Paper›PMID 42014743›Full record

ArticleScientific reports2026

Anti-obesity medication use sparks effort-based sanctions and social penalties.

Tassilo T Tissot, Leopold H O Roth

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tassilo T Tissot *Department of Developmental, Personality, and Social Psychology, Faculty of Psychology and Educational Sciences, Ghent University, Ghent, Belgium. tassilo.tissot@ugent.be.
Leopold H O Roth *Department of Occupational, Economic, and Social Psychology, Faculty of Psychology, University of Vienna, Vienna, Austria. leopold.roth@univie.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is one of the most widespread public health risks, with more than 1 billion affected individuals worldwide. While treatment with 'anti-obesity' medication (GLP-1 agonists) shows promising results, patients face public backlash for 'cutting corners'. Across four pre-registered within-subject studies in three countries (N = 1.205, Belgium, US, UK), we found that users of GLP-1 medication are perceived as less moral, presumably because they are thought to have exerted less effort in their weight-loss endeavor. Further, we observed effects on broader consequences (e.g., competence or deservingness perceptions) and tested candidate moderators (e.g., attitudes, experience, personality). Our findings highlight the adverse consequences of effort-based biases experienced by patients using anti-obesity medication and underscore the need for public education and stigma reduction.

Indexed as

Anti-Obesity AgentsObesityAdultFemaleGlucagon-Like Peptide 1HumansMaleWeight LossAnti-Obesity AgentsGlucagon-Like Peptide 1Anti-obesity medicationBiasEffort moralizationJudgmentPreregistration

Identifiers

PMID42014743
PMCPMC13100314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.